Closed System Drug Transfer Device Market

Increasing incidences of cancer across the globe

The increasing incidences of cancer across the globe are significantly driving the global closed-system drug transfer device (CSTD) market. This is because cancer treatment often requires hazardous drugs that can be harmful to healthcare workers handling them. The system provides a closed and leak-proof system that helps the escape of these hazardous drugs into the environment. Further, the cancer burden is rising across the globe due to factors such as an aging population, environmental factors, better diagnostic capabilities, and lifestyle changes that are fostering market growth.

For instance, according to the International Agency for Research on Cancer, there were cancer cases of nearly 9,826,539 in Asia, 4,471,422 in Europe, 2,673 174 in Northern America, 1,551,060 in Latin America and the Caribbean, 1,185,216 in Africa, and 269 088 in Oceania in 2022. As per the International Agency for Research on Cancer, there were 192,020 breast cancer cases, 143,759 lips, oral cavity, 127,526 cervix uteri, 81,748 lung, 70,637 esophagus, 70,038 colorectum, and 727,588 cancer cases of others.

The growing focus on occupational safety, coupled with technological advancements in CSTD functionality and design, is accelerating its adoption across healthcare facilities worldwide. Also, healthcare providers prioritize both provider's and patients’ health; the demand for CSTDs is expected to continue in response to the escalating cancer burden worldwide.

Closed System Drug Transfer Device Market

The Global Closed System Drug Transfer Device Market Industry is projected to experience substantial growth over the coming years. The market is expected to reach 1.2 USD Billion in 2024 and is forecasted to grow to 3.84 USD Billion by 2035, indicating a robust CAGR of 11.15% from 2025 to 2035. This growth trajectory reflects the increasing demand for safe drug transfer solutions in healthcare settings, driven by factors such as regulatory compliance, technological advancements, and rising awareness of occupational hazards. The market dynamics suggest a promising future for closed system drug transfer devices.

The Global Closed System Drug Transfer Device Market Industry is poised for growth as healthcare infrastructure expands globally. Emerging economies are investing in healthcare facilities to improve patient care and safety standards. This expansion includes the establishment of oncology centers and specialized clinics that require safe drug handling solutions. As these facilities become operational, the demand for closed system drug transfer devices is expected to rise significantly. The focus on enhancing healthcare infrastructure aligns with the global trend towards safer drug administration practices, further propelling the market for closed system drug transfer devices.

The Global Closed System Drug Transfer Device Market Industry is witnessing a surge in the adoption of stringent safety standards aimed at minimizing exposure to hazardous drugs. Regulatory bodies are emphasizing the need for closed systems to protect healthcare workers and patients alike. For instance, the implementation of guidelines by the Occupational Safety and Health Administration (OSHA) has prompted healthcare facilities to invest in closed system devices. This trend is expected to drive the market, as organizations seek compliance with safety regulations, thereby enhancing the demand for closed system drug transfer devices.

The Global Closed System Drug Transfer Device Market Industry is experiencing growth due to heightened awareness of occupational hazards associated with hazardous drug handling. Healthcare professionals are increasingly recognizing the risks posed by exposure to cytotoxic drugs, leading to a demand for safer handling practices. Educational initiatives and training programs are being implemented to inform healthcare workers about the dangers and the importance of using closed system devices. This awareness is fostering a cultural shift towards prioritizing safety in healthcare settings, thereby driving the adoption of closed system drug transfer devices across various healthcare facilities.

The Global Closed System Drug Transfer Device Market Industry is significantly influenced by the increasing prevalence of cancer and chronic diseases. As the number of patients requiring chemotherapy and other hazardous drug therapies rises, the demand for safe drug handling solutions escalates. According to projections, the market is anticipated to grow from 1.2 USD Billion in 2024 to 3.84 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 11.15% from 2025 to 2035. This growth is largely driven by the need for effective and safe drug administration methods, highlighting the critical role of closed system drug transfer devices.

The Global Closed System Drug Transfer Device Market Industry is benefiting from rapid technological advancements in drug delivery systems. Innovations such as improved materials and design features enhance the safety and efficacy of drug transfer processes. For example, the introduction of devices with integrated safety features reduces the risk of contamination and exposure to hazardous substances. These advancements not only improve user experience but also align with the evolving needs of healthcare providers. As technology continues to evolve, the market for closed system drug transfer devices is likely to expand, driven by the demand for more sophisticated and reliable solutions.

Based on region, the Closed System Drug Transfer Device Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 9.92 billion by 2032, registering a CAGR of 9.10% during the forecast period.

North America accounted for the largest market share of 38.14% and is estimated to dominate the global CSTD market. This large market share is due to the increasing prevalence of cancer cases and the strong research and development infrastructure. For instance, In the United States in 2020, there were 1,603,844 new cancer cases reported and 602,347 cancer deaths. There were 403 new cancer cases reported for every 100,000 people, and 144 people died from cancer. Moreover, Technological advancements in CSTDs are further driving market growth.

Modern devices incorporate innovative features such as air filtration systems, leak-proof connectors, and enhanced compatibility with various drug delivery systems, thereby improving their effectiveness and usability in clinical settings

The Americas region is followed by Europe, which accounted for the second largest closed system drug transfer device market share. One of the primary drivers is the increasing prevalence of chronic diseases across the region, which necessitates efficient and safe drug delivery mechanisms. This demographic trend is fueling demand for advanced drug transfer devices that offer enhanced safety and precision in medication administration. Additionally, stringent regulations and guidelines pertaining to healthcare worker safety are pushing healthcare facilities to adopt closed-system drug transfer devices (CSTDs) to minimize occupational exposure to hazardous drugs.

Moreover, technological advancements in drug transfer devices, such as the integration of smart features and materials that ensure compatibility with a wide range of medications, are further propelling market expansion. These factors collectively contribute to a favorable landscape for growth in the Europe drug transfer devices market, promising continued innovation and adoption in the years ahead.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest growing region over the forecast period due to the increasing number of new vendors involved in the drug-device system, as many regional/small market players are trying to leverage the market share. In 2019, there were only 62 dedicated cancer care hospitals in India, including both regional and national facilities, according to the National Institute of Health. The estimated number of cancer incidents in India for the year 2022 was 14,61,427 (crude rate: 100.4 per 100,000).

In India, one in every nine people will develop cancer during their lifetime. Lung and breast cancers were the most common cancer sites in men and women, respectively. Thus, the increasing cancer patient pool will propel the demand for closed drug delivery systems which will boost the market growth in the region. Additionally, the availability of skilled workforce and low production cost in the region portrays an opportunity for global players to enter untapped markets in Asia-Pacific.

FIGURE 3: CLOSED SYSTEM DRUG TRANSFER DEVICE MARKET BY REGION 2023 & 2032 (USD BILLION)

The Closed System Drug Transfer Device Market is characterized by the presence of many global, regional, and local vendors. The market is highly competitive, with all the players competing to gain maximum market share. Intense competition, frequent changes in government policies, and regulations are key factors that impact market growth. The vendors compete based on cost, product quality, reliability, and aftermarket services.

Product launch and approvals were also observed to expand the company's product portfolio. The growth of prominent industry players is dependent on various factors, such as market conditions, product differentiation and innovation, and pricing strategies. It is also projected that increasing investment in healthcare infrastructure and rising awareness and education associated with the closed system drug transfer device (CSTDs) benefits will also boost the market's growth in the upcoming future. 

Major players in the Closed System Drug Transfer Device Market, including Becton, Dickson, and Company, Inc, Baxter International Inc., ICU Medical, Inc., JMS Co.Ltd, B. Braun SE, Equashield, and others are making investments in R&D activities to boost market demand.

Braun is a healthcare supplier and manufacturer that offers its products to hospitals, surgical units, private practices (medical care and doctors' offices), and extracorporeal blood treatments. The company operates through three major business segments: Hospital Care, Aesculap, and Avitum. Furthermore, B. Braun offers a wide range of medical devices and systems for hospitals and healthcare facilities. They invest significantly in research and development (R&D) to introduce new products, improve existing ones, and address unmet medical needs.

Moreover, In December 2021, B. Braun Medical Inc. has introduced the next generation OnGuard 2 CSTD in the United States. Building on the strengths of its predecessor, OnGuard 2 incorporates upgraded materials and enhanced features aimed at improving usability while retaining all the existing advantages of the original OnGuard device.